CBLL

CeriBell has delivered a sharp move over the past year, which naturally puts its current share price under the microscope. The question for you is whether the recent trading level lines up with what the business is generating through its sales.

America’s planned AI build-out faces funding strains and project delays, yet the race to add computing power has not stopped.

CeriBell, Inc. previously announced that the FDA cleared new software for its Ceribell System, adding bedside brain-activity trend tools like Alpha-Delta Ratio and amplitude-integrated EEG to help clinicians interpret complex EEG data more quickly across…

CeriBell (CBLL) drew investor attention after the FDA cleared new software for its Ceribell System, expanding bedside EEG tools that help clinicians read complex brain activity data more quickly in critical care.

New clearance to further simplify bedside EEG interpretation and enable more informed interventions for patients of all ages across multiple indicationsSUNNYVALE, Calif., Sept.

Strong growth driven by new FDA clearances, Delirium NTAP approval, and expanding account base despite widening net losses.

Revenue surged 33% as hospital accounts expanded and delirium reimbursement neared launch.

Although the revenue and EPS for CeriBell, Inc. (CBLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of -13.33% and +3.22%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?